Premium
Treatment outcomes and prognostic factors of feline splenic mast cell tumors: A multi‐institutional retrospective study of 64 cases
Author(s) -
Evans B. J.,
O'Brien D.,
Allstadt S. D.,
Gregor T. P.,
Sorenmo K. U.
Publication year - 2018
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/vco.12305
Subject(s) - cats , splenectomy , medicine , chemotherapy , retrospective cohort study , mast cell , spleen , gastroenterology , oncology , immunology
Background Mast cell tumors (MCT) are common splenic tumors in cats, but there is limited information on treatment outcomes of cats with this disease. Materials and methods This retrospective study evaluated treatment outcomes in 64 cats with splenic MCT. Cats were categorized into the following treatment groups: splenectomy (A, n = 20); splenectomy with chemotherapy (B, n = 20); chemotherapy alone (C, n = 15); or supportive care (D, n = 9). Results Median tumor specific survival (MTSS) was: 856, 853, 244, 365 days for groups A, B, C, and D, respectively. The MTSS was not significantly different between the 4 groups. However, comparing cats that had splenectomy (A and B) versus those that did not (C and D), the MTSS was 856 and 342 days, respectively (p=0.008). None of the prognostic factors analyzed significantly influenced survival. Conclusion Splenectomy (+/‐ chemotherapy) significantly prolongs survival in cats with mast cell tumors. The role of chemotherapy remains unknown.